ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1996;62:1459
© 1996 The Society of Thoracic Surgeons

Discussion

Discussion

The first 20% of the full text of this article appears below.

See also page 1454.

DR LARRY R. KAISER (Philadelphia, PA): I thank The Society for giving me the privilege of discussing this report, and I congratulate Dr Snider and associates on this preliminary work. Unfortunately, they did not provide me with a copy of their manuscript, so my comments are, per force, based only on the abstract.

Targeted antineoplastic therapy that is specific for tumor cells and nontoxic to normal cells is indeed the goal in the treatment of malignant disease. Currently no such therapy exists. Any benefit derived from therapy unfortunately carries a price. Antibody conjugate therapies, like the one you . . . [Full Text of this Article]


Related Article

c-erbB-2/p185–Directed Therapy in Human Lung Adenocarcinoma
John M. Snider, Lamar J. Bushnell, Lih C. Chen, and Louis A. Lanza
Ann. Thorac. Surg. 1996 62: 1454-1459. [Abstract] [Full Text]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.